Brain Advance Access originally published online on February 4, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain, Vol. 127, No. 3, 671-679, 2004
© 2004 Guarantors of Brain
doi: 10.1093/brain/awh078
Calpain inhibition protects against Taxol-induced sensory neuropathy
Departments of 1 Neurology and 2 Pathology, Emory University School of Medicine, Atlanta, GA, and 3 School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA
Correspondence to: Jonathan D. Glass, MD, Emory Center for Neurodegenerative Disease, Whitehead Biomedical Research Building, 615 Michael Street, 5th Floor, Mailstop 194100700, Atlanta, GA 30322, USA E-mail: jglas03{at}emory.edu
Taxol is a highly effective anticancer agent that causes peripheral neuropathy as its major toxic side effect. The neuropathy is characterized by degeneration of sensory axons that may be severe enough to be dose limiting. Axonal degeneration involves the activation of the calcium-activated proteases calpains, and here we tested whether systemic inhibition of calpains with the peptide 
-ketoamide calpain inhibitor AK295 can reduce the clinical and pathological effects of Taxol in a rodent model of Taxol neuropathy. In mice with Taxol neuropathy, AK295 reduced the degree of axonal degeneration in sensory nerve roots, and improved clinical measures of neuropathy, including behavioural and electrophysiological function. These findings were consistent for both 3- and 6-week models of neuropathy. In vitro, Taxol caused activation of both calpains and caspases in PC12 cells. AK295 inhibited the activation of calpains but did not interfere with the antimitotic effects of Taxol on microtubules, nor did it inhibit caspase-mediated cell death. These data implicate calpains in the pathogenesis of Taxol neuropathy, and demonstrate that AK295 can prevent axonal degeneration and clinical neuropathy in mice. In addition, AK295 did not interfere with the primary antineoplastic effects of Taxol on microtubules and cell death, suggesting that systemic calpain inhibition may be a good strategy for preventing neuropathy in patients being treated with Taxol.
Key Words: axon; axonal degeneration; calpain; paclitaxel; peripheral neuropathy
Abbreviations: DMEM = Dulbecco’s modified Eagle’s medium; DMSO = dimethyl sulfoxide; DRG = dorsal root ganglia
Received August 21, 2003. Revised November 12, 2003. Accepted November 13, 2003.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Boehmerle, K. Zhang, M. Sivula, F. M. Heidrich, Y. Lee, S.-E. Jordt, and B. E. Ehrlich Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation PNAS, June 26, 2007; 104(26): 11103 - 11108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Burke, B .J. Traynor, L . Bruijn, R . Conwit, F . Beal, G . O'Neill, S .C. Fagan, and M .E. Cudkowicz Neuroprotective agents for clinical trials in ALS: A systematic assessment Neurology, February 27, 2007; 68(9): 709 - 710. [Full Text] [PDF]
|
|
|
|
|
|
W. Boehmerle, U. Splittgerber, M. B. Lazarus, K. M. McKenzie, D. G. Johnston, D. J. Austin, and B. E. Ehrlich Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism PNAS, November 28, 2006; 103(48): 18356 - 18361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bianchi, M. Brines, G. Lauria, C. Savino, A. Gilardini, G. Nicolini, V. Rodriguez-Menendez, N. Oggioni, A. Canta, P. Penza, et al. Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity Clin. Cancer Res., April 15, 2006; 12(8): 2607 - 2612. [Abstract] [Full Text] [PDF]
|
|